Clinical Trial Update: Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating safety, PK/PD, immunogenicity, and clinical activity of GSK2857916 in adults with multiple myeloma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GSK2857916

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2019-09-26